Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999577 | 0.97 | GSK3B (0.56) | GSK3BCYP1A2CYP2D6DRD2DRD4 | |
| SCHEMBL4001235 | 0.94 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4005262 | 0.93 | GSK3B (0.54) | GSK3BCYP1A2CYP2D6DRD2DRD4 | |
| SCHEMBL3998498 | 0.90 | GSK3B (0.47) | GSK3B | |
| SCHEMBL4001336 | 0.90 | GSK3B (0.54) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL4000340 | 0.89 | GSK3B (0.45) | GSK3BCYP1A2CYP2D6DRD2DRD4 | |
| SCHEMBL4001203 | 0.89 | GSK3B (0.47) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3996990 | 0.87 | GSK3B (0.43) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3999502 | 0.87 | GSK3B (0.46) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3999412 | 0.87 | GSK3B (0.52) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027078-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | US | claimed |
| US-20060014762-A1 | 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | claimed |
| US-6974819-B2 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo{1,2-a}pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2005-12-13 | — | — | US | claimed |
| EP-1315731-B1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-20040087598-A1 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI (FR) | 2004-05-06 | — | — | US | claimed |
| EP-1184385-A1 | 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2002-03-06 | — | — | EP | claimed |
| US-7566720-B2 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20080027078-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | US | disclosed |
| US-20060014762-A1 | 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
| US-6974819-B2 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo{1,2-a}pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2005-12-13 | — | — | US | disclosed |
| EP-1315731-B1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-20040087598-A1 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI (FR) | 2004-05-06 | — | — | US | disclosed |
| EP-1184385-A1 | 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087598-A1 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives | CBR1, DPYD, SULT1E1 | GSK3B 4758/4885CYP1A2 438/4885CYP2D6 17/4885 |
| US-20060014762-A1 | 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives | DPYD, CBR1, TXN2 | GSK3B 4812/4885CYP1A2 586/4885CYP2D6 12/4885 |
| US-20080027078-A1 | 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES | PSEN2, PSEN1, GSK3A | GSK3B 4/4885CYP1A2 1648/4885CYP2D6 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.